Fig. 3: Olaparib effects in CRISPR/Cas9-edited del(11q) cells in vitro, in vivo and in combination with ibrutinib. | Leukemia

Fig. 3: Olaparib effects in CRISPR/Cas9-edited del(11q) cells in vitro, in vivo and in combination with ibrutinib.

From: CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition

Fig. 3

a HG3-edited clones were treated with 3 μM olaparib and cell viability was assessed by MTT every 2 days up to 12 days. Proliferation rates are presented as MTT absorbance units, and data are shown as mean ± SD. P values indicate differences between HG3WT and HG3-del(11q) ATMKO clones. b Kaplan–Meier overall survival curve of HG3WT (n = 10) and HG3-del(11q) ATMKO (n = 10) xenografted mice treated with olaparib (n = 6) or vehicle (n = 4). The reported P value was calculated by Log-rank test. c Left panel: immunoblot analysis of whole-cell lysates of HG3WT and HG3-del(11q) ATMKO cells exposed to 5 μM olaparib and ibrutinib, either alone or in combination, after 48 h. Right panel: cytotoxicity studies by annexin V/PI staining of HG3WT and HG3-del(11q) cells treated with 5 μM olaparib and ibrutinib for 48 h. Cytotoxicity is measured as the percentage of PI + and annexin V + cells. Data are summarized as the mean ± SD of four independent experiments.

Back to article page